| Document |
Document Title |
|
WO/2020/097950A1 |
Disclosed is a method for preparing polyisocyanate. A self-polymerization reaction of isocyanate is carried out using a fluorine-containing catalyst as a catalyst. After the reaction is completed, a fluorine-containing terminator is adde...
|
|
WO/2020/014524A1 |
This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-...
|
|
WO/2019/217449A1 |
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2 are as defined herein. The present invention also contemplates ...
|
|
WO/2019/154288A1 |
Disclosed in the present invention are a cationic compound, a preparation method therefor and a use thereof. Provided by the present invention is a compound represented by formula I having a novel structure, or a pharmaceutically accepta...
|
|
WO/2019/135604A1 |
The present invention relates to a method for producing a lactam compound from dioxazolone in the presence of a catalyst having a particular ligand, and to a lactam compound produced thereby, and can produce a lactam compound with excell...
|
|
WO/2019/109402A1 |
The present invention pertains to the technical field of pesticides, and particularly relates to a dioxazine derivative, a preparation method therefor, an herbicidal composition containing the same, and an application thereof. The chemic...
|
|
WO/2019/091975A1 |
The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.
|
|
WO/2019/087087A1 |
The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programme...
|
|
WO/2019/055657A1 |
The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and pro...
|
|
WO/2019/052545A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in b...
|
|
WO/2019/034660A1 |
The invention relates to a method for producing polyisocyanates which comprise at least 10 mol% of iminooxadiazinedione groups based on the sum total of the iminooxadiazinedione and isocyanurate groups present in the polyisocyanate, by r...
|
|
WO/2019/025562A1 |
The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ph...
|
|
WO/2018/206635A1 |
The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an act...
|
|
WO/2018/197523A1 |
The invention relates to novel compounds of formula (I) and their use in medicine, particularly in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Additionally, the i...
|
|
WO/2018/178982A1 |
It is an object of the present invention to provide a novel and advantageous process for commercially preparing of indoxacarb which is racemic or enantiomerically enriched at chiral center from its amide precursor using a new catalytic s...
|
|
WO/2018/157813A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...
|
|
WO/2018/137387A1 |
Provides a crystalline form of indoxacarb, the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. Also provides the use of various...
|
|
WO/2018/120093A1 |
Provided are a process for preparing an oxadiazacyclo compound and the use thereof. An N-alkoxycarbonyl hydrazine is cyclized with a disubstituted ether under the action of an alkali to give an N-alkoxycarbonyl oxadiazacyclo compound, an...
|
|
WO/2018/093920A1 |
The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the natural...
|
|
WO/2018/089951A1 |
Chemoselective conjugation is achieved through redox reactivity by reacting an N- transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Ch...
|
|
WO/2018/039430A1 |
Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expres...
|
|
WO/2018/009417A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.
|
|
WO/2017/202481A1 |
The invention relates to the use of l-(4,6-dipentyl-5,6- dihydro-2H-l,2,3-oxadiazin-2-yl)-3-hydroxypropan-l-one in treating and /or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Add...
|
|
WO/2017/194452A1 |
The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, ...
|
|
WO/2017/156074A1 |
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or medi...
|
|
WO/2017/116702A1 |
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used fo...
|
|
WO/2017/101553A1 |
Disclosed are a fluorene multifunctional photoinitiator as represented by general formula (I), a photosensitive resin composition containing same, and the preparation thereof and uses of the two. The compound has the advantages of simple...
|
|
WO/2017/031325A1 |
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...
|
|
WO/2017/030728A1 |
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.
|
|
WO/2016/201168A1 |
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...
|
|
WO/2016/193822A1 |
A process for preparing (E)-(5,6-dihydro-l,4,2-dioxazin-3-yl)(2- hydroxyphenyl)methanone O-methyl oxime is described which includes: (i) reacting benzofuran-3(2H)-one O-methyl oxime (1) with at least one nitrite selected from n-butyl nit...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/187534A1 |
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasi...
|
|
WO/2016/106284A2 |
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...
|
|
WO/2016/040458A2 |
18F labeled ID01 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a l-fluoro-2-halo-4- aminobenzene and a 4-amino-N-hydroxy-l,2,5-oxadiazole-3-carboximidoyl chlorid...
|
|
WO/2015/195686A1 |
A polyoctatriazacane molecule is disclosed that has a plurality of octatriazacane groups having the structure (I); and a plurality of divalent bridging groups, each divalent bridging group comprising an aromatic group.
|
|
WO/2015/155230A1 |
The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates fr...
|
|
WO/2015/078116A1 |
The present invention relates to a process for preparing isocyanate homopolymers containing uretdione groups, in which the phosphinoboron compound of formula (I) are used as catalysts to catalyze the homopolymerization reaction of raw is...
|
|
WO/2015/033303A1 |
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The i...
|
|
WO/2015/011071A1 |
The present invention relates to a process for producing polyisocyanates containing iminooxadiazinedione groups, by oligomerizing at least one monomeric di- and/or triisocyanate in the presence of a) at least one catalyst, b) at least on...
|
|
WO/2015/011068A1 |
The present invention relates to a method for producing polyisocyanates which contain iminooxadiazine dione groups and in which at least one monomeric di- and/or triisocyanate is oligomerized in the presence of at least one catalyst and ...
|
|
WO/2015/011069A1 |
The invention relates to a method for producing polyisocyanates-containing iminooxadiazinedione groups, wherein at least one monomeric di- and/or triisocyanate is oligomerized in the presence of a) at least one catalyst, b) at least one ...
|
|
WO/2014/202697A1 |
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of preparation and uses thereof, pharmaceutical compositions in particular to be used as chitinase inhibitors in the treatment of a fungal infection.
|
|
WO/2014/198620A1 |
The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrin...
|
|
WO/2014/147231A1 |
The application relates to a catalyst kit comprising a trimerization catalyst for the asymmetric trimerization of polyisocyanates and a catalyst poison for the trimerization catalyst, which is characterized in that the trimerization cata...
|
|
WO/2014/078690A1 |
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
|
|
WO/2014/074365A1 |
The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridem...
|
|
WO/2014/069620A1 |
The present invention is a method for producing a liquid composition with a pH of 10.0 or more comprising tetrahydro-4H-1,3,5-oxadiazine-4-one and water by reacting urea and formaldehyde in water, the molar feed ratio of formaldehyde/ure...
|
|
WO/2014/040709A1 |
The present invention relates to a compound of formula (1) wherein X1 represents O or NR6, X2 represents O or NR6, X3 represents O or NR1, R1 represents H or C1 to C3 alkyl, R2 represents H, or a linear or branched C1 - C8 alkyl optional...
|
|
WO/2014/028669A1 |
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma rec...
|
